Abstract: Methods and compositions for modulating transforming growth factor-beta (TGF?) biological activity in a vertebrate subject in need thereof. The methods involve administering to the vertebrate subject an effective amount of a substance capable of modulating activity of LEMD3 in the vertebrate subject to thereby modulate TGF? biological activity in the vertebrate subject.
Type:
Grant
Filed:
October 9, 2019
Date of Patent:
January 3, 2023
Assignees:
University of Virginia Patent Foundation, Emory University
Inventors:
Thomas H. Barker, Leandro Moretti, Dwight M. Chambers
Abstract: Disclosed are methods of treating a disorder or disease associated with myotonic dystrophy. Methods of treating a CNS dysfunction and/or cognitive impairment associated with myotonic dystrophy in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of treating a myotonic dystrophy associated disease or disorder caused by mis-splicing of GABRG2 in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of improving cognitive function or alertness in a subject having myotonic dystrophy comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed.
Type:
Grant
Filed:
May 10, 2018
Date of Patent:
December 20, 2022
Assignees:
Emory University, University of Florida Research Foundation, Inc.
Inventors:
Gary Bassell, Andrew Jenkins, David B. Rye, Maurice Scott Swanson, Eric Tzy-Shi Wang, Lyndon Lien
Abstract: This disclosure relates to inhibitors of Mcl-1 stimulated homologous recombination (HR) DNA repair and uses for treating cancer. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an inhibitor of Mcl-1 in combination with other anti-cancer agents, e.g., that induce DNA replication stress. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering compounds disclosed herein in combination with hydroxyurea, olaparib, or combinations thereof.
Type:
Grant
Filed:
October 23, 2018
Date of Patent:
December 13, 2022
Assignee:
Emory University
Inventors:
Xingming Deng, Guo Chen, Abu Syed Md Anisuzzaman
Abstract: This disclosure relates to the use of kinase inhibitor to treat or prevent infectious diseases such as tuberculosis. In certain embodiments, this disclosure relates to treating or preventing an infectious disease comprising administering an effective amount of a kinase inhibitor or other compound disclosed herein to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing tuberculosis comprising administering a kinase inhibitor to a subject in need thereof. In certain embodiments, the subject is diagnosed with Mycobacterium tuberculosis (Mtb) that is resistant to multiple antibiotic agents.
Abstract: This disclosure relates bis-amine compounds disclosed herein and uses related to CXCR4 inhibition. In certain embodiments, the compounds have formula I, salts, derivatives, and prodrugs thereof wherein, A is an bridging aryl or heterocyclyl and R1 and R2 are further disclosed herein. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising compounds disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing CXCR4 related diseases or conditions by administering an effective amount of a compound disclosed herein to a subject in need thereof.
Type:
Grant
Filed:
June 18, 2020
Date of Patent:
December 6, 2022
Assignees:
Emory University, Georgia State University Research Foundation, Inc.
Inventors:
Hyunsuk Shim, Suazette Reid Mooring, Renren Bai
Abstract: The systems and methods can provide continuous, efficient, accurate, non-contact, monitoring of one or more cardiorespiratory and/or behavior parameters associated with a subject in a defined environment using at least non-contact sensor data and provide feedback based on the determined parameters. The system can include one or more sensor modules disposed within defined environment(s). The system may further include one or more sensors disposed at a specific spatial location in the defined environment. The sensor(s) may include non-contact electric field sensor(s) configured to record non-contact sensor data related to one or more periods of stillness and/or movement of the subject. The system may further include one or more processors configured to determine cardiorespiratory respiratory parameters and/or behavior parameters using the non-contact sensor data.
Type:
Grant
Filed:
April 25, 2017
Date of Patent:
November 29, 2022
Assignee:
Emory University
Inventors:
Shawn Hochman, William Goolsby, Michael McKinnon, Camden MacDowell, Heidi Kloefkorn-Adams
Abstract: Provided herein are fluid formulations for administration to a suprachoroidal space of an eye of a patient. The fluid formulations may include a pharmaceutical agent, a binding molecule, or a combination thereof. The pharmaceutical agent and the binding molecule may be bonded to each other covalently, non-covalently, or a combination thereof. The pharmaceutical agent may be configured to bond to an ocular tissue. The binding molecule may be configured to bond to an ocular tissue. Methods of administering the fluid formulations, methods of expanding a suprachoroidal space, and methods of reducing the minimum force to separate the sclera and choroid are provided.
Type:
Grant
Filed:
July 20, 2017
Date of Patent:
November 22, 2022
Assignees:
Emory University, Georgia Tech Research Corporation
Abstract: Compositions, non-viral vectors, recombinant viruses, and recombinant viral vectors for inhibiting ?FosB expression or activity in a cell and for treating dyskinesia in a subject (e.g., a human patient having Parkinson's disease and Levodopa-induced dyskinesia) include a nucleic acid sequence encoding a shRNA specific for ?FosB. Methods of using these compositions, non-viral vectors, recombinant viruses, and recombinant viral vectors are also described herein. These compositions, non-viral vectors, recombinant viruses, and recombinant viral vectors and methods of use provide novel therapies for dyskinesia based on the reduction of ?FosB expression and/or activity.
Type:
Application
Filed:
November 2, 2020
Publication date:
November 17, 2022
Applicants:
Rutgers, The State University of New Jersey, Emory University
Inventors:
Mary M. Mouradian, Stella Papa, Jie Zhang, Goichi Beck
Abstract: The systems, devices and methods provide customizable and adjustable support to anatomical tissue or organs, such as pelvic, vaginal, uterine, cervical, bladder, rectal, among others, or any combination thereof. The anatomical support device may include a support member having a periphery that surrounds an opening. The support member may be configured to releasably and adjustably expand between one or more expanding states from a resting state and contract to the resting state. The support member may include a first portion and a second portion disposed along the periphery. Each portion may include a passage cross-sectional area and a wall thickness. The first wall thickness and/or the first passage cross-sectional area of the first portion may be different from the second wall thickness and/or the second passage cross-sectional area of the second portion.
Abstract: The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.
Type:
Grant
Filed:
February 21, 2018
Date of Patent:
November 15, 2022
Assignee:
Emory University
Inventors:
Dennis Liotta, Edgars Jecs, Robert James Wilson, Huy Hoang Nguyen, Michelle Bora Kim, Lawrence Wilson, Eric James Miller, Yesim Altas Tahirovic, Valarie Truax
Abstract: Aspects of the subject disclosure may include, for example, a non-transitory, machine-readable medium, comprising executable instructions that, when executed by a processing system including a processor, facilitate performance of operations including receiving a call; selecting a next carrier to handoff the call; generating a call data record (CDR) for the handoff to the next carrier; encrypting the CDR using a call encryption key, thereby creating an encrypted CDR; encrypting the encrypted CDR using a committee encryption key, thereby creating a double encrypted CDR; recording the double encrypted CDR to a blockchain; and sending the call encryption key to the next carrier. Other embodiments are disclosed.
Type:
Application
Filed:
May 10, 2021
Publication date:
November 10, 2022
Applicants:
AT&T Intellectual Property I, L.P., Emory University
Abstract: The present disclosure relates to Zika vaccines. In certain embodiments, this disclosure relates to vaccine compositions for use in methods of protecting a human subject against Zika disease or infection, wherein said composition comprises a vaccinal for Zika such as a live attenuated or inactivated chimeric Zika virus; live attenuated Zika virus; an inactivated Zika virus; a replication-defective pseudo-infectious Zika virus; a Zika virus-like particle (VLP), a Zika protein or combinations thereof. In certain embodiments, the Zika vaccinal comprises or encodes altered polypeptide sequences disclosed herein.
Type:
Grant
Filed:
December 6, 2018
Date of Patent:
November 8, 2022
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc.
Abstract: In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.
Type:
Grant
Filed:
September 18, 2020
Date of Patent:
October 18, 2022
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc.
Inventors:
Martin L. Moore, Jia Meng, Anne Hotard, Elizabeth Littauer, Christopher Stobart
Abstract: This disclosure relates to methods of treating cancer or viral infections comprising administering an effective amount of a VIP antagonist in combination with an immune check-point inhibitor to a subject in need thereof. In certain embodiments, the immune check-point inhibitor is an anti-PD1 or anti-PDL1 antibody.
Type:
Grant
Filed:
April 24, 2019
Date of Patent:
October 18, 2022
Assignees:
Emory University, Georgia Tech Research Corporation
Inventors:
Edmund K. Waller, Rebecca Pankove, Susan Thomas, Sruthi Ravindranathan
Abstract: The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
Type:
Grant
Filed:
December 15, 2020
Date of Patent:
October 18, 2022
Assignees:
Emory University, US Govt represented by Dept of Veterans Affairs
Abstract: This disclosure relates to synthetic coupling methods using catalytic molecules. In certain embodiments, the catalytic molecules comprise heterocyclic thiolamide, S-acylthiosalicylamide, disulfide, selenium containing heterocycle, diselenide compound, ditelluride compound or tellurium containing heterocycle.
Type:
Grant
Filed:
October 9, 2020
Date of Patent:
October 18, 2022
Assignee:
Emory University
Inventors:
Lanny Steven Liebeskind, Pavan Kumar Reddy Gangireddy
Abstract: Inhibition of the VIP signaling pathway with VIP antagonist is contemplated. In certain embodiments, the disclosure relates to methods of enhancing the immune response to a cell therapy comprising administering a VIP antagonist to a subject in combination with a cell. In certain embodiments, the subject is diagnosed with leukemia or lymphoma. In certain embodiments, the cell is a blood cell, bone marrow cell, leukocyte, T-cell, natural killer cell, a hematopoietic stem cell, a G-CSF mobilized or non-mobilized blood mononuclear cell.
Type:
Grant
Filed:
May 22, 2017
Date of Patent:
October 11, 2022
Assignee:
Emory University
Inventors:
Edmund K. Waller, Jian-Ming Li, Mohammad S. Hossain
Abstract: This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.
Type:
Grant
Filed:
January 31, 2017
Date of Patent:
October 11, 2022
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc., Georgia Tech Research Corporation, Chapman University
Inventors:
Wilbur A. Lam, Caroline Hansen, Yumiko Sakurai, Andrew Lyon
Abstract: Techniques are provided for generating and processing compressed sensor data. Sensor signals can be collected using one or more sensors. The sensor signals can be compressed using a compression data structure. In some instances, the compressed signal corresponds to a sampling rate at or below the Nyquist sampling rate. The compressed signal can be compared to one or more templates. Events within the compressed signal can be detected and characterized based on the comparison.
Type:
Grant
Filed:
March 22, 2018
Date of Patent:
October 4, 2022
Assignees:
Emory University, Universita degli Studi di Udine
Inventors:
Giulia Di Poian, Roberto Rinaldo, Gari Clifford
Abstract: Disclosed are compounds to the treatment of infectious diseases and methods of treating such diseases. The compounds are derivatives of clevudine.